Crysvita burosumab-twza 30mg/m injection

Quantity

Get it to United States within 10 working days with standard delivery.

Fast delivery to United States

Easy Returns & Exchanges

Ask About This Product

Condition : New

0

From UAE

To United States

in 5-10 days

Description

Crysvita (burosumab-twza) is a monoclonal antibody used for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients. Each injection contains 30 mg/mL of burosumab-twza. Crysvita works by binding to and inhibiting the activity of fibroblast growth factor 23 (FGF23), a hormone that plays a key role in phosphate metabolism. This action helps to increase serum phosphate levels and improve bone health.

How It Works

Burosumab-twza targets and binds to FGF23, a hormone that reduces phosphate reabsorption by the kidneys and decreases vitamin D production. By inhibiting FGF23, Crysvita increases renal phosphate reabsorption and stimulates the production of active vitamin D (1,25-dihydroxyvitamin D). This leads to increased serum phosphate levels and improved mineralization of bones, addressing the underlying pathophysiology of XLH.

Indications

  • X-linked hypophosphatemia (XLH) in adult and pediatric patients

Contraindications

  • Hypersensitivity to burosumab-twza or any component of the formulation
  • Patients with severe renal impairment or end-stage renal disease
  • Patients with high serum phosphate levels

Side Effects

  • Injection site reactions (pain, redness, swelling)
  • Headache
  • Fever
  • Vomiting
  • Cough
  • Nausea
  • Constipation
  • Dizziness
  • Muscle spasms
  • Increased blood pressure
  • Hyperphosphatemia (excess phosphate levels)

Price in Different Countries

Country Price (per 30mg/mL injection) References
United States $9,000 GoodRx Crysvita Price
United Kingdom £7,500 NHS Crysvita Price
Canada $11,000 Canada Drugs Crysvita Price
Australia $10,500 PBS Crysvita Price
India ₹650,000 1mg Crysvita Price

Top 5 Global Brands

  • Crysvita (Ultragenyx Pharmaceutical Inc. and Kyowa Kirin): The original brand of burosumab-twza, approved for the treatment of XLH.
  • Burosumab (Various Generic Manufacturers): Generic versions of burosumab are becoming available, providing more options for patients.
  • Regeneron (Regeneron Pharmaceuticals): Known for its advancements in monoclonal antibody therapies, Regeneron is a key player in the biologics market.
  • Roche (Hoffmann-La Roche): A leading global healthcare company that develops innovative pharmaceuticals and diagnostics, including monoclonal antibodies.
  • Amgen (Amgen Inc.): A biotechnology company known for its biologic therapies, including those targeting bone and kidney health.
Shopping Cart